425
Investor Presentation
February 25, 2015
Filed by Wright Medical Group, Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Wright Medical Group, Inc.
Commission File No.: 001-35823

This presentation includes forward-looking statements.  These forward-looking statements generally can be identified by the use of
words such as “anticipate,”
“expect,”
“plan,”
“could,”
“may,”
“will,”
“believe,”
“estimate,”
“forecast,”
“goal,”
“project,”
and other words of
similar meaning.  Forward-looking statements in this presentation include, but are not limited to, statements about our outlook for our
expected
financial
results
for
2015;
statements
about
the
approvable
status
and
anticipated
final
PMA
approval
of
Augment
®
Bone
Graft and the anticipated positive effects of such; and statements about the timing and anticipated benefits of the previously announced
merger with Tornier.  Each forward-looking statement contained in this presentation is subject to risks and uncertainties that could
cause
actual
results
to
differ
materially
from
those
expressed
or
implied
by
such
statement.
Applicable
risks
and
uncertainties
include,
among others, uncertainties as to the timing of the Tornier transaction; uncertainties as to whether Tornier shareholders and Wright
shareholders will approve the transaction; the risk that competing offers will be made; the possibility that various closing conditions for
the
transaction
may
not
be
satisfied
or
waived,
including
that
a
governmental
entity
may
prohibit,
delay
or
refuse
to
grant
approval
for
the consummation of the transaction, or the terms of such approval; the effects of disruption from the transaction making it more
difficult to maintain relationships with employees, customers, vendors and other business partners; the risk that shareholder litigation in
connection with the transaction may result in significant costs of defense, indemnification and liability; other business effects, including
the effects of industry, economic or political conditions outside of Wright’s or Tornier’s control; the failure to realize synergies and cost-
savings from the transaction or delay in realization thereof; the businesses of Wright and Tornier may not be combined successfully, or
such
combination
may
take
longer,
be
more
difficult,
time-consuming
or
costly
to
accomplish
than
expected;
operating
costs
and
business disruption following completion of the transaction, including adverse effects on employee retention and on Wright’s and
Tornier’s respective business relationships with third parties; transaction costs; actual or contingent liabilities; the adequacy of the
combined
company’s
capital
resources;
failure
or
delay
in
ultimately
obtaining
FDA
approval
of
Wright’s
Augment
®
Bone
Graft
for
commercial
sale
in
the
United
States,
failure
to
achieve
the
anticipated
benefits
from
approval
of
Augment
®
Bone
Graft,
and
the
risks
identified
under
the
heading
“Risk
Factors”
in
Wright’s
Annual
Report
on
Form
10-K,
which
was
filed
with
the
SEC
on
February
26,
2015,
and
Tornier’s
Annual
Report
on
Form
10-K,
filed
with
the
SEC
on
February
24,
2015,
as
well
as
both
companies’
subsequent
Quarterly Reports on Form 10-Q and other information filed by each company with the SEC.  Investors should not place considerable
reliance on the forward-looking statements contained in this presentation.  You are encouraged to read Wright’s and Tornier’s filings
with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in
this
presentation
speak
only
as
of
the
date
of
this
release,
and
Wright
undertakes
no
obligation
to
update
or
revise
any
of
these
statements.  Wright’s business is subject to substantial risks and uncertainties, including those referenced above.  Investors, potential
investors,
and
others
should
give
careful
consideration
to
these
risks
and
uncertainties.
Cautionary Note Regarding Forward-Looking Statements       
2

Wright and Tornier use non-GAAP financial measures, including EBITDA, as adjusted. Their respective
management
teams
believe
that
the
presentation
of
these
measures
provides
useful
information
to
investors and that these measures may assist investors in evaluating their respective company’s
operations, period over period. EBITDA is calculated by adding back to net income charges for interest,
income taxes and depreciation and amortization expenses. While it is not possible to reconcile the
adjusted EBITDA forecast in this presentation to the nearest metric under U.S. generally accepted
accounting principles (GAAP) of the combined business without unreasonable effort, the adjusted EBITDA
forecast excludes non-cash stock based compensation expense and non-operating income and expense,
as well as the expected impact of such items as transaction and transition costs, impacts from the sale of
Wright’s OrthoRecon business and costs associated with distributor conversions and non-competes, all of
which
may
be
highly
variable,
difficult
to
predict
and
of
a
size
that
could
have
substantial
impact
on
the
combined company’s reported results of operations for a period. Investors should consider these non-
GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial
performance prepared in accordance with GAAP.
Note on Non-GAAP Financial Measures
3

In connection with the proposed merger, Tornier has filed with the U.S. Securities and Exchange Commission (SEC) a
registration statement on Form S-4 that includes a preliminary joint proxy statement of Wright and Tornier that also
constitutes a preliminary prospectus of Tornier. The registration statement is not complete and will be further amended.
Wright and Tornier will make the final joint proxy statement/prospectus available to their respective shareholders.
Investors are urged to read the final joint proxy statement/prospectus when it becomes available, because it will contain
important information. The registration statement, definitive joint proxy statement/prospectus and other documents filed
by Tornier and Wright with the SEC will be available free of charge at the SEC’s website (www.sec.gov) and from Tornier
and Wright. Requests for copies of the joint proxy statement/prospectus and other documents filed by Wright with the
SEC may be made by contacting Julie D. Tracy, Senior Vice President and Chief Communications Officer by phone at
(901) 290-5817 or by email at julie.tracy@wmt.com, and request for copies of the joint proxy statement/prospectus and
other
documents
filed
by
Tornier
may
be
made
by
contacting
Shawn
McCormick,
Chief
Financial
Officer
by
phone
at
(952) 426-7646 or by email at shawn.mccormick@tornier.com.
Important Additional Information and Where To Find It
4
Wright, Tornier, their respective directors, executive officers and employees may be deemed to be participants in the
solicitation of proxies from Wright’s and Tornier’s respective shareholders in connection with the proposed transaction.
Information about the directors and executive officers of Wright and their ownership of Wright stock is set forth in Wright’s
annual report on Form 10-K for the fiscal year ended December 31, 2014, which was filed with the SEC on February 26,
2015, and its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on March 31,
2014. Information regarding Tornier’s directors and executive officers is contained in Tornier’s annual report on Form 10-K
for the fiscal year ended December 28, 2014, which was filed with the SEC on February 24, 2015, and its proxy statement
for its 2014 annual general meeting of shareholders, which was filed with the SEC on May 16, 2014. These documents
can be obtained free of charge from the sources indicated above. Certain directors, executive officers and employees of
Wright and Tornier may have direct or indirect interest in the transaction due to securities holdings, vesting of equity
awards and rights to severance payments. Additional information regarding the participants in the solicitation of Wright
and Tornier shareholders will be included in the joint proxy statement/prospectus.

Recent Updates
•
Completed successful $632.5 million convertible debt offering:
–
Maturity: February 15, 2020
–
Coupon: 2.00%
–
Effective conversion price: $40.00
–
Added ~$275 million in cash to balance sheet
•
Received Second Request from FTC in connection with proposed
merger with Tornier:
–
All products identified are lower extremity products and accounted for, in
the
aggregate,
global
revenue
~$21
million
/
U.S.
revenue
~$14.9
million
–
Time to close is important, so Company has begun taking steps to
explore divestiture option for lower extremity products
–
Economics and strategic rationale of transaction will not materially be
affected
–
2Q 2015 close possible, but best-case scenario
5

The New Wright Medical:
Global Leader in Extremities-Biologics
Global
Extremities-
Biologics
market
~$8B
Wright Medical
position in
Extremities market
post Tornier merger
Wright Medical
growth rate
vs. the market
#1
~2X
6

Agenda
Strong Performance Record
Augment
®
Approval:  A Game Changer
Pending Transaction Creates Premier
High-Growth Extremities-Biologics Company
The Future:  Outperforming
in Growth Markets
7

Entering a New Growth Era
2012
2014
Future
2011
Multiple markets,  
slow growth
Repositioned as   
high growth, pure
play in Extremities
Transformational merger,
global powerhouse in
Extremities-Biologics
8

Strategic Priorities
Global leader
in
Extremities
Improve sales force productivity
Customer conversion process
International expansion
Rapid
Augment
®
adoption
(once
approved)
1.
Accelerate
Global
Revenue
Growth
World class supply chain
(cost & inventory)
2.
Improve
Gross
Margin and
Inventory
•
Successful merger integration
•
Leverage corporate costs
•
Leverage U.S. sales and
marketing investments
3.
Improve
EBITDA
Key Priorities
Execute an effective compliance program and
continue to successfully execute CIA
=  2015 Vital Few Initiative
9

Focused on Higher Growth Segments of the
Orthopedics Market
Source:  2014 iData Research Inc., 2013 Millennium Research Group, 2012 Life Science Intelligence, Management Estimates
Wright Medical focus
Tornier
10
10%
7-8%
7%
8-9%
6%
3-4%
3%
2-3%
Foot &
Ankle
Sports
Medicine
Biologics
Upper
Extremities
Trauma
Knee
Spine
Hip

RESULTS:
Created Extremities Pure Play with Strong Momentum
Primary Focus: Foot & Ankle
(Breakdown of 2014 Sales)
Foot &
Ankle
Upper
Extremity
Biologics
Other
66%
9%
22%
3%
Growth in line with goals
Strong Sales Momentum
(Continuing Operations)
~20%
CAGR
11
$214M
$242M
$298M
2012
2013
2014

Agenda
Strong Performance Record
Augment
®
Approval:  A Game Changer
Pending Transaction Creates Premier 
High-Growth Extremities-Biologics Company
The Future:  Outperforming
in Growth Markets
12

Augment
®
Bone Graft –
A Breakthrough Product
•
First clinically proven, cost-effective alternative
to autograft for ankle and/or hindfoot fusion indications
•
Demonstrates equivalent safety & efficacy with less pain
•
Only synthetic growth factor to market in last 10 years
•
Bone repair
•
Soft tissue indications                                         
(tennis elbow & rotator cuff repair)
•
Recombinant human platelet-derived growth factor   
(rh-PDGF) stimulates bone formation
•
Provides a scaffold for new bone growth
•
Avoids unwanted bone formation in surrounding tissues
observed with BMP-based products
Unique
Solution
Breakthrough
Biologic
Platform for
Future
Growth
13

Augment
®
–
A High Potential Platform Technology
Bone
Soft Tissue
Market potential (US)
$300M
Market potential (US)
$1B+
•
Ankle Fusion
•
Hindfoot Fusion
•
Chronic
Tendinopathy
(Tennis Elbow)
•
Rotator Cuff
Repair
1
st
Target
Market
•
Approval anticipated 1H of 2015
•
Company’s
2015
guidance
includes
U.S.
Augment
®
revenue of $10 million to $12 million assuming approval
of Augment
®
Bone Graft by mid-2Q 2015
Future
rh-PDGF
Clinical
Study
Opportunities
14

Agenda
Strong Performance Record
Augment
®
Approval:  A Game Changer
Pending Transaction Creates Premier 
High-Growth Extremities-Biologics Company
The Future:  Outperforming
in Growth Markets
15

Transaction Overview
•
All stock –
combined equity value of ~$3.3B at announcement
–
combined entity will be incorporated in the Netherlands
–
combined company ownership:  52% Wright / 48% Tornier
•
Transaction is subject to customary closing conditions, including:
–
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended
–
Wright and Tornier shareholder approval
•
Second quarter 2015 closing still possible, but best-case scenario
16

Tornier at A Glance
•
Extremities company with leadership
position in Upper Extremities
•
NASDAQ: TRNX
•
HQ in Netherlands; operations run out of
U.S., France and Ireland
•
2014 revenue:  $345M
•
Products sold in 45 countries
–
~42% of revenue outside U.S.
•
1,076 employees globally
Aequalis Ascend
Flex Shoulder System
Latitude EV Elbow
Prosthesis
Salto Talaris Total
Ankle Prosthesis
CannuLink Intraosseous
Fixation System
Sports Med
& Biologics
Upper
Extremity
62%
17%
17%
4%
Lower
Extremity
Large
Joint
Primary Focus:  Upper Extremity
(Breakdown of 2014 Sales)
17

A
D
V
A
N
T
A
G
E #
1
Combination Creates Most Comprehensive
Upper and Lower Extremity Product Portfolio
Upper Extremities
Upper Extremities
Lower Extremities
Lower Extremities
9%
of revenue
62%
of revenue
66%
of revenue
17%
of revenue
Complementary Product
Portfolios
Market leading
positions
in high-growth
markets
18

A
D
V
A
N
T
A
G
E #
2
Combining Two Innovative Companies Enhances
Future Growth Prospects
INFINITY
®
Total Ankle
Replacement System
Recent
Product
Launches
PRO-TOE
®
offering for Hammertoe
correction
Recent
Product
Launches
Aequalis
Ascend Flex
convertible shoulder
platform
Phantom Fiber
high strength
resorbable suture
Reverse
Threaded
Baseplate
19
Dedicated R&D will power innovation across combined portfolio

A
D
V
A
N
T
A
G
E #
3
Accelerates Growth Opportunities in Three Large,
Fast Growing Markets
Market Growth
(2014-2018 CAGR)
Upper
Extremity
Lower
Extremity
Biologics
~$7.9B
$5.5B
Augment
®
Bone Graft launch;
Cross-sell Biologics across
expanded Extremities portfolio
Leverage scale across
geographies and categories
Expanded Opportunities
Wright Medical enters
Upper Extremities market with
leadership position in shoulder
8-9%
8-10%
20
5-6%
2014
2018

A
D
V
A
N
T
A
G
E #4
Creates Mid-Size Growth Company with Stronger
Financial Profile
Scale and scope to accelerate path to profitability
Upper
Extremity
Lower
Extremity
Biologics &
Sports Med
Large Joints
& Other
~$298M
~$345M
Combined Sales
$600M+
37%
Upper
Extremity
40%
Lower
Extremity
12%
Bio*
11%
Lg Joints
Solid Financial Profile
Revenue Breakdown
(2014 revenue)
*Excludes Augment
®
Bone Graft
21
Once integrated:
•
Accretive to combined
adj.
EBITDA
in
2
nd
full
year
post merger
•
Annual cost synergies of
$40M-$45M by year 3
•
Adj. EBITDA margins
approaching 20% in
3-4 years
•
High 70s% gross margin
•
Mid-teens revenue growth

Unique Positioning Will Continue to Set Us Apart
V I S I O N
Premier High-Growth Extremities-Biologics Company
SPECIALIZED
SALESFORCES
TECHNOLOGY
LEADER
GLOBAL
FOOTPRINT
Dedicated to serving the needs of specialty surgeons
22

Agenda
Strong Performance Record
Augment
®
Approval:  A Game Changer
Pending Transaction Creates Premier 
High-Growth Extremities-Biologics Company
The Future:  Outperforming
in Growth Markets
23

Longer Term –
Continue to Execute Proven Strategy
Completely focused:
Extremities-Biologics technology leader
1
Specialized sales forces:
Drive productivity
2
International expansion:
Key market focus, drive adoption
3
New product launches: 
Augment
®
breakthrough product
4
Sustainable, high-growth
Extremities market growing
in 8-10% range
Time
$
24

Priorities Next 1-2 years
Ensure smooth integration
-
integration planning is underway
Continue to execute our operating initiatives
-
including sales productivity, new product
launches, medical education
Launch Augment
®
Bone Graft in U.S.
-
Subject to FDA approval
25
Close merger with Tornier
-
2Q 2015 close possible, but best-case scenario

A
C
L
O
S
E
R
L
O
O
K
A
T
K
E
Y
I
N
I
T
I
A
T
I
V
E
S
Strong Pipeline of New Product Introductions
AUGMENT
®
Bone Graft
•
Proven therapeutic option
•
$300M  U.S. market opportunity
•
Pending FDA approval
2014
2015
2016
INFINITY
®
Total Ankle System
•
Third generation design
•
Further penetrate end-stage ankle
arthritis market opportunity
SIMPLICITI™
•
Will be first minimally invasive shoulder
option in U.S.
•
$200M-$250M market opportunity
In rollout
2017
Launch Date
26
•
Physician testing anticipated in 2015
•
Pending FDA clearance
INVISION™
Revision System

A CLOSER LOOK AT MERGER:
Clear Line of Sight to Deliver Cost Synergies from Merger
•
Public company expenses
•
Overlapping support functions
•
Overlapping systems
•
Vendor consolidation
•
Process improvement
Key Synergy Areas
Year 3
Annual Cost
Synergies:
$40M-$45M
27

Advancing Toward Our Goals
28
Goals
Once Integrated With Tornier
Sales growth
Mid teens
Gross Margin
High 70s% range
Adj. EBITDA margin
Adj. EBITDA margins approaching
20% in 3 to 4 years

Revenue
(1, 2)
Adj. EBITDA
(1)
$325M to $335M
$(27M) to $(22M)
2015 Guidance for Wright Standalone Company
29
1
Guidance range communicated  on 2/25/2015. The fact that we include these projections in this presentation should not be taken to
mean
that
these
amounts
continue
to
be
our
projections
as
of
any
subsequent
date.
2
Guidance
range
is
on
standalone
Company
basis
and
assumes
final
approval
of
Augment
®
Bone
Graft
by
mid-Q2
of
2015.
Represents
constant
currency
growth
of
13%
to
16%
from
2014.
Range
assumes
U.S.
Augment
®
revenue
of
$10
million
to
$12
million
and
a
negative
impact
from
currency
of
approximately
$12
million,
or
4%,
reflecting
the
recent
strengthening
of
the
U.S.
dollar
as
compared
to 2014,
and excludes any potential dis-synergies from the pending merger with Tornier.  

I N
S U M M A R Y
The New Wright Medical: Global Leader in Extremities
30
Solid Performance Record
Augment
®
Approval:
A Game Changer
Pending Transaction
Creates Premier Extremities-
Biologics Company
The Future: Outperforming
in Growth Markets
•
Unmatched capabilities,
unique mid-cap growth asset
•
Built market leader
•
Multiple growth drivers,
accelerated path to profitability
•
High potential platform technology

Investor Presentation
February 25, 2015